Siemens Healthineers AG (SHLN) Stock Price & Analysis
SHLN Stock Chart & Stats
- Day’s Range
- MXN 861.51 - MXN 861.51
- 52-Week Range
- MXN 585.00 - MXN 1,090.00
- Previous Close
- MXN 861.51
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 1.01T
- Enterprise Value
- MXN 50.98B
- Total Cash (Recent Filing)
- MXN 2.36B
- Total Debt (Recent Filing)
- MXN 15.00B
- Price to Earnings (P/E)
- 21.7
- Beta
- -0.10
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- 14.13
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 2.63%
Bulls Say, Bears Say
Bulls Say
Diversified Recurring Revenue Model
Siemens Healthineers earns from large equipment sales plus annuity-like service contracts, consumables and software subscriptions. That multi-stream model supports durable revenue resilience, repeatable margins and predictable installed-base cash flow over the medium term.
Strong Profitability And FCF Generation
Sustained high gross and operating margins and material free cash flow provide capacity to reinvest in R&D, fund service networks and deleverage. Persistent FCF conversion underpins strategic flexibility and supports long-term operational commitments and capital allocation.
Equipment Demand, Market Share Gains And Product Innovation
Rapid adoption of differentiated imaging tech (photon-counting CT, DryCool MR) and strong order intake indicate durable competitive advantages. Sustained market-share gains and validated product leadership help maintain equipment placement, future service revenue and long-term growth.
Bears Say
Diagnostics Weakness And China Revenue Rebase
A prolonged Diagnostics decline, amplified by a China market rebase, erodes a high-frequency revenue pool (consumables/assays). Slower recovery in China reduces the predictability of recurring diagnostic volumes and risks longer-term dilution of segment margins and share.
Refinancing And Rising Interest Expense Pressure
Upcoming higher-cost refinancing increases recurring net interest expense, weakening net income and free cash flow. That structural funding cost rise can slow deleveraging, reduce resources for capex/R&D and constrain long-term financial flexibility if margins soften.
Uneven Cash‑flow Conversion And Revenue Volatility
Volatile cash conversion driven by working-capital swings and investment timing creates forecasting risk and can force short-term financing or deferred investments. Structural variability limits certainty around funding for new product launches and sustained deleveraging.
Siemens Healthineers AG News
SHLN FAQ
What was Siemens Healthineers AG’s price range in the past 12 months?
What is Siemens Healthineers AG’s market cap?
When is Siemens Healthineers AG’s upcoming earnings report date?
How were Siemens Healthineers AG’s earnings last quarter?
Is Siemens Healthineers AG overvalued?
Does Siemens Healthineers AG pay dividends?
What is Siemens Healthineers AG’s EPS estimate?
How many shares outstanding does Siemens Healthineers AG have?
What happened to Siemens Healthineers AG’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Siemens Healthineers AG?
What is the TipRanks Smart Score and how is it calculated?
Siemens Healthineers AG Stock Smart Score
Company Description
Siemens Healthineers AG
Siemens Healthineers AG, a subsidiary of Siemens Aktiengesellschaft with its headquarters in Erlangen, Germany, is a global leader in medical technology. The company develops, produces, and distributes a comprehensive portfolio of diagnostic and therapeutic products and services, catering to healthcare providers worldwide. Its operations are organized into four distinct business segments. The Imaging segment delivers advanced medical imaging systems, encompassing magnetic resonance imaging (MRI), computed tomography (CT), X-ray technology, molecular imaging, and ultrasound solutions. The Diagnostics segment focuses on providing in-vitro diagnostic products and services for laboratory, molecular, and point-of-care applications, alongside workflow optimization tools and informatics solutions for healthcare facilities. Varian, another key segment, specializes in cancer care, offering cutting-edge technologies, services, and integrated solutions to hospital oncology departments. This includes enhancing workflow efficiency, providing clinical services and consulting, and deploying digital platforms for treatment and therapy management. Lastly, the Advanced Therapies segment supplies sophisticated products designed to facilitate image-guided minimally invasive treatments across various medical fields, such as cardiology, interventional radiology, and surgery. Its offerings include angiography systems, mobile C-arms, and a robotic-assisted platform specifically for endovascular coronary and peripheral vascular procedures. Beyond these core offerings, Siemens Healthineers also provides a suite of essential support services, such as equipment performance management, clinical education and e-learning programs, asset management, managed departmental services for laboratories and healthcare facilities, and expert consulting and digital health services.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Bernhard Montag
- Employees
- 74,300
- Website
- www.siemens-healthineers.com
- Address
- Siemensstr. 3, Forchheim, BV, 91301, DE
Siemens Healthineers AG (SHLN) Earnings & Revenues
SHLN Company Deck
SHLN Earnings Call
Earnings Call SentimentNeutral
The call showed a mix of strong operational and product‑led momentum (notably book‑to‑bill strength, Precision Therapy/Varian growth, imaging innovations, radiopharma traction and improved cash/net‑debt) while Diagnostics weakness—driven by China's market rebasing and legacy platform dilution—kept top‑line momentum below prior expectations and led management to lower revenue guidance. Profitability and EPS were supported by tariff refunds and the synergetic core remains on track, but inflation, FX, refinancing and separation costs create tangible near‑term headwinds. Overall the positives around core growth, market share gains, strong orders and cash improvement are materially offset by the Diagnostics decline and macro/one‑off uncertainties, leaving a balanced outlook.
View all MX:SHLN earnings summariesSHLN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 2 | 4 |
| Technical Analysis | 4 | 2 | 3 |
| Moving Averages | 11 | 0 | 1 |